Trillium Asset Management LLC Has $275,000 Stake in Illumina, Inc. (NASDAQ:ILMN)

Trillium Asset Management LLC reduced its holdings in Illumina, Inc. (NASDAQ:ILMN) by 21.6% during the 4th quarter, Holdings Channel reports. The institutional investor owned 2,061 shares of the life sciences company’s stock after selling 567 shares during the quarter. Trillium Asset Management LLC’s holdings in Illumina were worth $275,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Versant Capital Management Inc grew its holdings in shares of Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 146 shares in the last quarter. Golden State Wealth Management LLC bought a new position in Illumina in the fourth quarter valued at approximately $32,000. Assetmark Inc. increased its position in shares of Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after purchasing an additional 296 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Illumina during the 4th quarter worth approximately $45,000. Finally, TD Private Client Wealth LLC boosted its holdings in shares of Illumina by 58.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after buying an additional 141 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Stock Down 0.2 %

NASDAQ ILMN opened at $84.96 on Thursday. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The company has a market cap of $13.46 billion, a price-to-earnings ratio of -11.06, a PEG ratio of 1.60 and a beta of 1.17. The company has a 50 day moving average of $110.28 and a 200-day moving average of $128.89. Illumina, Inc. has a 1-year low of $80.18 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Barclays restated an “underweight” rating on shares of Illumina in a report on Tuesday, March 11th. TD Cowen lowered shares of Illumina from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $177.00 to $140.00 in a research note on Friday, February 7th. Piper Sandler raised their target price on shares of Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Stephens reiterated an “overweight” rating and set a $156.00 price target on shares of Illumina in a report on Tuesday, March 11th. Finally, HSBC lowered Illumina from a “buy” rating to a “hold” rating and set a $100.00 price objective on the stock. in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $140.90.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.